Objectives: Statins are commonly used for the primary and secondary prevention of cardiovascular events; however, statins are underused in patients with noncoronary atherosclerosis. We sought to establish the rates of statin use in patients with carotid artery disease, and examine the association between statin therapy and clinical outcomes among an elderly population after carotid artery revascularization.
Methods: In this population-level, retrospective cohort study, we identified all individuals 66 years old who underwent carotid endarterectomy or stenting in Ontario, Canada, between 2002 and 2014. We used the Ontario Drug Benefit database to establish preprocedural and postprocedural statin use and dose on the basis of actual medication prescriptions filled. We classified statin intensity based on the 2013 American College of Cardiology/American Heart Association Guidelines on the Treatment of Blood Cholesterol. The primary outcome was a composite of 1-year stroke, myocardial infarction, or death. Adjusted hazard ratios (HRs) were computed using inverse probability of treatment weighting based on propensity scores.
Results: A total of 7893 of 10,723 patients (73.6%) who underwent carotid revascularization were on preprocedural statin therapy; moderate or high-dose therapy was used by 7384 patients (68.9%; Fig 1) . The mean age of patients in the statin group was 74.7 6 5.6 years and 75.6 6 6.2 years in the nonstatin group (n ¼ 2830); about one-third were female and approximately 45% had symptomatic carotid disease in both groups. The composite rate of 1-year stroke, myocardial infarction, or death was lower among statin users (adjusted HR, 0.76; 95% confidence interval [CI] , 0.70-0.83). Individual rates of stroke (adjusted HR, 0.76; 95% CI, 0.67-0.86), myocardial infarction (adjusted HR, 0.81; 95% CI, 0.69-0.95), and death (adjusted HR, 0.76; 95% CI, 0.67-0.87) were also lower with statin use, and the beneficial associations with statin use were observed regardless of the type of carotid revascularization procedure, carotid artery symptom status, or statin dose (Fig 2) .
Conclusions: Statin therapy was associated with an approximately 25% lower risk of adverse cardiovascular events in patients with significant carotid artery disease. Along with other supportive evidence, statins should be considered in patients undergoing carotid revascularization, and efforts are required to increase statin use in this undertreated population. PC064. Objectives: Three-dimensional (3D) image fusion is associated with lower radiation exposure, contrast dose, and operative time during endovascular abdominal aortic aneurysm repair. However, its impact on cerebrovascular intervention is unknown. Therefore, we evaluated the use of this technology during carotid artery stenting (CAS).
Methods: We identified consecutive CAS procedures from 2009 to 2017 and compared those performed with and without 3D image fusion. For image fusion, we created a 3D reconstruction of the aortic arch based on preoperative computed tomography or magnetic resonance angiography that we merged with live fluoroscopy, providing 3D image overlay. We compared radiation exposure, fluoroscopy time, contrast dose, time to common carotid artery (CCA) cannulation, time from CCA cannulation to completion angiogram, and total procedure time in procedures with and without image fusion. We also assessed rates of 30-day stroke/death and acute kidney injury. We used multivariable linear regression to adjust for patient and procedural characteristics, and used these models to compute the marginal effects of image fusion use.
Results: Forty-six patients underwent CAS with 3D image fusion and 70 without. Patients undergoing CAS with image fusion experienced 31% lower radiation exposure compared with the control group (207 6 22.7 mGy vs 300 6 25.6 mGy, respectively; P < .01), shorter fluoroscopy time (20.8 6 6.2 minutes vs 23.9 6 8.2 minutes; P ¼ .02), shorter time to carotid cannulation (21.4 6 9.1 minutes vs 30.9 6 8.2 minutes; P < .001), and shorter total procedure time (47.0 6 13.1 minutes vs 53.9 6 17.8 minutes; P ¼ .03). There was no difference in contrast volume or time from CCA cannulation to completion angiogram. After multivariable adjustment, 3D image fusion remained associated with lower radiation dose, shorter fluoroscopy time, and shorter time to carotid cannulation (all P < .05; Fig) . The rate of 30-day stroke/death was 2.7% (three strokes and no deaths at 30 days), and the rate of acute kidney injury was 1.8%.
Conclusions: CAS with 3D image fusion is associated with a lower radiation exposure and shorter time to CCA cannulation. These results indicate the potential technical advantage gained with image fusion during this complex endovascular procedure. Although too early into its implementation to confirm, this technology also may decrease stroke risk during CAS by minimizing manipulation of the aortic arch. Objectives: Transcarotid artery revascularization (TCAR) provides an attractive alternative to carotid endarterectomy (CEA) and transfemoral stenting for high-risk patients by using a direct carotid approach with cerebral blood flow reversal for embolic protection. The purpose of this study was to compare outcomes from patients with carotid artery stenoses treated by TCAR versus a matched control group undergoing CEA.
Methods: The records of all patients who underwent TCAR at 3 institutions between 2013 and 2017 were retrospectively reviewed. TCAR patients had high-risk factors and were enrolled in prospective trials (ROADSTER 1, ROADSTER 2) or were treated after US Food and Drug Administration approval of the Enroute Neuroprotection System (Silk Road Medical, Inc, Sunnyvale, Calif). Contemporaneous patients undergoing CEA at each institution were also reviewed. Patients were matched in a 2:1 (CEA:TCAR) fashion with respect to age at time of surgery (3 years), gender, and symptomatic status. Data was analyzed using univariate statistical models with P < .05 considered significant.
Results: Overall, 789 patients (Table) were identified. In the entire cohort, patients undergoing the TCAR procedure were higher risk patients with an increased prevalence of diabetes (P ¼ .018), coronary artery disease (P < .001), and tobacco use (P ¼ .020) compared with CEA patients. Stroke rates at 30 days (1.4% vs 1.8%) and 1 year (2.9% vs 1.8%) were not statistically different between the groups. However, mortality was significantly higher in the CEA group at 30 days (1.9% vs 0%; P ¼ .04) and 1 year (6.6% vs 1.8%; P ¼ .04). When matched 2:1, a cohort of 501 patients (167 TCAR, 334 CEA) with mean follow-up of 28.7 months (range, 3-59 months) remained. Patients undergoing TCAR were treated pharmacologically more aggressively with both preoperative and postoperative aspirin (P < .001), clopidogrel (P < .001), and statins (P < .001). Stroke rates were 2.4% CEA versus 1.8% TCAR at 30 days and 3.6 versus 1.8% at 1 year (P ¼ NS). Hematoma, cranial nerve injury, and myocardial 
